Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Medullary thyroid carcinoma (MTC) lacks effective treatments for recurrent or metastatic stages.
• MTC often involves inherited or acquired RET mutations in thyroid C-cells.
• Targeting tyrosine kinase activity is a potential therapeutic strategy.

Purpose of the Study:

• To investigate the efficacy of novel pyrazolopyrimidine derivatives as src-family tyrosine kinase inhibitors.
• To evaluate the sensitivity of human MTC cell lines to a specific compound, Si 34.
• To assess the impact of Si 34 on MTC cell growth and mortality.

Main Methods:

• Utilized two human MTC cell lines: TT (MEN2A RET mutation) and MZ-CRC-1 (MEN2B RET mutation).
• Incubated cells with the pyrazolopyrimidine derivative Si 34 for 6 days.
• Assessed cell growth inhibition, cell mortality, and indicators of apoptosis (biochemical and morphological).

Main Results:

• Si 34 demonstrated significant growth inhibitory effects in both TT (approx. 90%) and MZ-CRC-1 (approx. 80%) cell lines.
• The primary mechanism of growth inhibition was enhanced cell mortality.
• No biochemical or morphological signs of apoptosis were observed at concentrations increasing cell mortality.

Conclusions:

• The novel tyrosine kinase inhibitor Si 34 effectively reduces MTC cell growth through increased cell mortality.
• Further validation in preclinical in vivo models is warranted.
• Si 34 presents a promising candidate for the development of new MTC therapies.